Case report reveals lung adenocarcinoma in a patient initially treated for tuberculosis, highlighting the need for accurate diagnosis.
Pulmonary tuberculosis (TB) remains highly prevalent in endemic regions; however, current international and national guidelines emphasize microbiological confirmation prior to initiation of anti-tubercular therapy (ATT) whenever feasible. Empirical treatment without microbiological confirmation represents a deviation from recommended standards and may contribute to diagnostic delay. We report a 52-year-old male presenting with chronic cough with mucoid expectoration and progressive dyspnea without fever, hemoptysis, or weight loss. Despite negative sputum acid-fast bacilli (AFB) smear and cartridge-based nucleic acid amplification test (CBNAAT), the patient was empirically initiated on ATT based on clinicoradiological suspicion. Lack of clinical and radiological response prompted further evaluation. High-resolution computed tomography (HRCT) demonstrated persistent consolidation with perilymphatic nodules and interlobular septal thickening. Positron emission tomography-computed tomography (PET-CT) revealed metabolically active pulmonary lesions with mediastinal lymphadenopathy and a suspicious adrenal lesion. CT-guided biopsy confirmed moderately differentiated lung adenocarcinoma. Molecular analysis revealed a KRAS mutation with negative programmed death-ligand 1 (PD-L1) expression. This case underscores the importance of adherence to diagnostic guidelines, early reconsideration of diagnosis in non-resolving consolidation, and the critical role of timely tissue diagnosis in preventing delays in oncological management.
No takes yet. Share an insight, caveat, or question.
Saxena et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: